• RVL Pharmaceuticals’ CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year’s H.C. Wainwright Annual Global Investment Conference in New York City
• The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis
• RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year
• The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company, recently announced that its CEO Brian Markison will be participating in a fireside chat and hosting 1-on-1 investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Tuesday, September 12, 2023. Mr. Markison will be discussing the company and its commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, also known as ptosis or low-lying eyelid(s), in adults (https://ibn.fm/097y6).

UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (“FDA”) for acquired blepharoptosis. The company obtained the necessary FDA approvals in July 2020 – launching UPNEEQ(R) in September 2020 to a limited number of eye care professionals. The company began expanding its commercial operations in 2021 to include ophthalmology, optometry, and oculoplastic specialties. In 2022, UPNEEQ(R) was launched into the U.S. medical aesthetics market.

In 2022, the global medical aesthetics market had an estimated value of $13.9 billion. By 2027, the estimated value is expected to reach $23.4 billion, representing a compound annual growth rate (“CAGR”) of 11%. The market’s projected growth is attributed to the rising preference for minimally invasive aesthetic procedures over traditional surgical options (https://ibn.fm/Ny5DV).

UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also showed that UPNEEQ(R) was well tolerated by participants and is safe; side effects were similar to those experienced in the placebo group.

RVL Pharmaceuticals believes that the growth in the medical aesthetics and eye care markets will be driven by an aging population and an increased life expectancy, resulting in more consumers who desire improved appearance and well-being over a longer period. The company also anticipates other contributing factors that include the growing awareness, utilization, and improved accessibility of treatments due to an increase in physicians offering eye care and medical aesthetics services.

Low-lying lids can affect adults of all ages. A survey conducted by eye care providers and medical aesthetics specialists revealed they believe that approximately half of the adult patients visiting their practices are affected by drooping or low-lying eyelids. RVL Pharmaceuticals estimates that approximately 60% of adult women self-identify as having some degree of ptosis, indicating that they are bothered by the position of their eyelids.

UPNEEQ(R) customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults. Patients can purchase UPNEEQ(R) directly from eye care, medical aesthetic professionals, or RVL Pharmaceuticals’ wholly owned pharmacy, RVL Pharmacy LLC. To support patients, RVL Pharmaceuticals launched the Elevate platform this year, which enables UPNEEQ(R) orders and subscription refills across HCP practices and RVL Pharmacy patients.

RVL Pharmaceuticals’ near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. RVL is focused on raising patient and provider awareness of acquired ptosis through medical conferences, HCP and direct-to-consumer advertising, social media, and marketing partnerships.

The company’s fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference will be webcast and available live and via replay from the RVL Pharmaceuticals website under the Investors & News section. The playback will be accessible for up to 90 days after the conference’s conclusion.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

• XESP continues to affirm its commitment to optimizing companies’ growth, mainly through its managed service that offers digital activation and engagement solutions
• Its proprietary technology, the Digital Engagement Engine(TM), which utilizes automation, unique data management, and a modern workflow, has proven to offer what no other competitor offers in the market
• This product is founded on critical principles integral to building customer loyalty, among them the importance of meeting customers’ demands for the modern digital experience
• Through this proprietary technology, XESP offers a solution that makes addressing the changing consumer demands a lot easier, faster, and more efficient

Electronic Servitor Publication Network (OTCQB: XESP), is a digital engagement company and a market disruptor offering cutting-edge data analysis and intelligent technology to help enterprises reach their target markets. Through its managed service, which offers digital activation and engagement solutions, the company looks to provide superior intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, all tested avenues for elevating customer experiences and response.

XESP is focused on the use of evolving technologies to increase customer reach and spur organizational growth. The company’s proprietary technology, the Digital Engagement Engine(TM), is an example of the company’s focus on solutions that directly address clients’ digital engagement needs.

By utilizing a combination of automation, unique data management, and a modern workflow built on a microservices architecture, XESP can offer what no competitor offers in the market. The company has differentiated itself through this technology, offering a unique value proposition.

“The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.”

A recent Destination CRM article written by Trey Simonton of MadCap Software points to 4 ways for building customer loyalty (https://ibn.fm/VvNRK):

1. Meet customers’ demands for modern digital experiences
2. Leverage online guides to upsell related offerings
3. Use online tutorials and guides to attract new customers
4. Support growing customer calls for sustainability

XESP’s offering is founded on such basic principles, serving as the building blocks for the managed services the company provides and how it tailors its Digital Engagement Engine specifically to the needs of the intended customer.

For starters, for a business to build customer loyalty, it must more effectively meet customer demands, specifically for the modern digital experience that defines the industry today. With more sales being conducted online, digital experiences can no longer be ignored. In 2022, over 21% of global retail sales were all conducted online. This amounted to $5.7 trillion, with 2.14 billion people shopping online in 2020 (https://ibn.fm/n71pq). Meeting these people’s demands for the modern digital experience makes a massive difference between a successful and failed business today.

Another principle is leveraging online guides to upsell related offerings. With more customers today preferring self-service over calling a support center, more businesses are moving toward enabling this functionality, although live personal interactions can be kept as one of the options. XESP, through its technology, is helping to refine the process, offering innovative solutions that present offers for related products tailored to specific customers, their purchase history, and overall preferences.

This of course also complements the growing customer calls for sustainability, with 79% of consumers pushing for brands to focus on developing working practices that consider the environment.

As consumer demands continue to evolve, especially in this digital age, more businesses are learning the importance of the internet and are being forced to cater to the changing consumer demands. XESP, through its proprietary technology, offers a solution that makes the entire process easier, faster, and more efficient, with a guarantee of elevating customer experiences. By offering meaningful customer interactions, businesses can realize growth, higher customer retention, and customer satisfaction in the long run.

“That meaningful interaction drives a greater relationship with your audience and trust,” noted Peter Hager, XESP’s CEO. “Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face. And if we can do that online, which the Digital Engagement Engine helps you do, you’re going to produce better results,” he added (https://ibn.fm/1501i).

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• In July 2023, LSDI launched Twilight, a new sleep aid product
• The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions
• LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life
• Also in May 2023, the company announced a partnership with non-profit TheraPsil to advance medical psilocybin access and research
• LSDI announced in April 2023 that its board had approved the repurchase of up to 500,000 shares of its Class A common stock

Lucy Scientific Discovery (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry.

The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada).

The company’s mission is to make its products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs, including various mental health and addiction disorders. LSDI targets customers that include an increasing number of the leading universities, hospitals and other public, private and government institutions throughout the world that have launched research programs aimed at understanding the therapeutic potential of a range of psychedelic substances.

The company is headquartered in Victoria, British Columbia, Canada.

Products

LSDI produces a variety of high-quality natural, synthetic and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market. The company believes the emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness. LSDI is dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.

In Canada, the psychedelic compounds that LSDI is approved to produce under its Dealer’s License are regulated under the Controlled Drugs and Substances Act, or CDSA. Those compounds include:

• Psilocybin
• Psilocin
• Lysergic acid diethylamide, or LSD
• N,N-Dimethyltryptamine, or N,N-DMT
• 3,4-Methylenedioxymethamphetamine, or MDMA
• 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B

The company also sells its consumer psychotropic products directly online and through retailers. Those products, described as microdose mushroom formulations, include a sleep aid, Twilight, and a mindfulness enhancer, Mindful.

Market Opportunity

According to a report from Global Market Insights, the psychotropics drug market had an estimated value of $20.2 billion in 2022 and is projected to reach a value of nearly $37.6 billion by 2032. That represents a CAGR of 6.4% for the forecast period. Factors driving market growth include the increasing prevalence of mental disorders, technological advancements in drug development, a rising geriatric population and increasing healthcare expenditures, the report states.

A growing awareness of mental health issues and an effort to reduce the stigma surrounding psychiatric disorders have encouraged more individuals to seek help, which in turn boosts the market. In addition, advancements in neuroscience, pharmacology and drug development have led to the discovery of new and more effective central nervous system therapeutics.

Innovative treatments offering better outcomes with fewer side effects attract patients and healthcare providers, also driving market growth.

Management Team

LSDI’s executive team brings deep experience in the development and commercialization of products featuring controlled substances, as well as the navigation of regulatory structures applicable to these products.

Richard Nanula is Chairman and CEO of LSDI. He has more than 35 years of leadership experience at several of the largest companies in the world, having been a senior executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. He has also served as a board member for Boeing Corporation and Starwood Capital, where he provided corporate guidance and oversight. He holds an MBA from Harvard Business School.

Assad J. Kazeminy, Ph.D., is Chief Scientific Officer at LSDI. He previously served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, and he has founded several drug development companies. He has over 30 years of research and development experience in the biopharmaceutical industry. He received his Ph.D. in Pharmaceutical Science and Biochemistry from Esfahan University in Iran. He completed a Post Doctorate course of study at the University of Southern California Medical School, Department of Pharmacology.

Brian Zasitko, CPA, CA, is the company’s CFO. He is a Director of Invictus Accounting Group LLP, a professional services firm providing finance, advisory and accounting services. He also serves as CFO of Lobe Sciences Ltd., a company developing psychedelic compounds as therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. He has an undergraduate degree from Simon Fraser University and a CPA (“CA”) from Certified Professional Accountants, British Columbia.

For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI

• CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin
• The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM
• 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year
• Based on the results seen preclinically, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”), and neuro-oncology, recently announced the presentation of updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease (https://ibn.fm/yp5AC).

“Berubicin has demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease,” noted Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals.

So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks the data cutoff point for CNS Pharmaceuticals, a significant milestone toward reporting topline results before the end of the year.

“We are approaching the most important milestone to date since we launched CNS Pharma,” noted John Climaco, CNS Pharmaceuticals’ CEO.

“We are just a few months away from reporting topline results from our Berubicin potentially pivotal study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach full enrollment of the trial,” he added (https://ibn.fm/0Yy0n).

The primary endpoint of this study is Overall Survival (“OS”), a goal that the United States Food and Drug Administration (“FDA”) has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Approximately 50% of patients on both arms have completed the study, with each showing comparable demographics, including age, race, gender, KPS, and BSA. Based on the results seen preclinically and in the clinical study thus far, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients.

“Based on the results we’ve seen preclinically and in the clinic thus far, including these updated results from our ongoing potentially pivotal study, we remain optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients,” noted Dr. Silberman.

The FDA has already granted CNS Pharmaceuticals Fast Track Designation for Berubicin, allowing it more frequent interactions with the agency, both for guidance and review. In addition, the company has received Orphan Drug Designation from the FDA, affording it seven years of marketing exclusivity upon approval of an NDA. Progress from its ongoing study is inching closer to enjoying these benefits and more, and its management is optimistic that it will offer a more viable treatment option for GBM than what is already in the market.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• In June 2023, Longeveron filed with the SEC to offer subscription rights worth up to $30 million of shares of Class A common stock to stockholders and holders of warrants. The rights offering, which became effective on August 17, 2023, is being made through a distribution of five tradable subscription rights (listed on The NASDAQ Capital Market under the ticker symbol LGVNR) to purchase shares of Class A common stock for each share of common stock and warrant to purchase common stock owned as of the record date of August 18, 2023, at a $3.00 subscription price per share. The subscription period opened on August 22, 2023, and will continue until September 21, 2023, unless extended at the company’s sole discretion.
• During Q2 2023, the company announced children in its ELPIS I Trial of Lomecel-B(TM) for HLHS had 100% survival up to five years of age after receiving the drug, as compared with an approximate 80% survival rate in historical trials. Lomecel-B(TM) for HLHS has previously received Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”).
• In August 2023, the company announced the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (“NHLBI”) and using the company’s Lomecel-B(TM) asset in Hypoplastic Left Heart Syndrome (“HLHS”), has surpassed the 50% enrollment threshold. Additionally, the trial has activated its eighth clinical site location – one additional site beyond the seven originally planned – in order to try to expedite the completion of the trial enrollment.
• The company expects to share top-line results from its Phase 2a CLEAR MIND trial of Lomecel-B(TM) for the treatment of Alzheimer’s disease in early October 2023.
• Longeveron is conducting a Phase 2 study of Lomecel-B in patients with Aging-related Frailty in conjunction with Japan’s National Center for Geriatrics & Gerontology and Tokyo’s Juntendo University Hospital.

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease, and Aging-related Frailty.

The company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B(TM), an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B(TM) may address these conditions through multiple mechanisms of action (“MOA”) that simultaneously target key aging-related processes.

The company is headquartered in Miami, Florida.

Lomecel-B(TM)

Lomecel-B(TM) is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B(TM) has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (“MSCs”) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B(TM) is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B(TM) is administered via peripheral intravenous infusion, while, in the company’s HLHS trial, Lomecel-B(TM) is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B(TM) in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B(TM) of between $4 billion and $8 billion globally per year, according to company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B(TM), that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Forward-Looking Statements

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact 
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

• A field project review in June 2023 confirmed widespread mineralization at Appia’s Ionic Clay Project in Brazil
• The company’s highly experienced management team has more than 100 years of combined experience in the metals and minerals industry
• Appia’s Alces Lake project contains some of the highest-grade total critical REE mineralization in the world
• As of June 2023, the company had no debt

Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (“REE”) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (“RC”) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (“HREEs”) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (“LREEs”) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (“SSE”). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

• Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
• Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

For more information, visit the company’s website at www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

• Ucore Rare Metals Inc. is a supply chain innovator dedicated to establishing North American production of tech-critical rare earth elements (“REEs”), a resource currently dependent upon Chinese industry priorities and governmental policies
• Ucore recently hosted representatives from the U.S. Embassy in Canada for an exclusive tour of the company’s proprietary RapidSX(TM) REE processing demonstration facility in Ontario
• The tour underscores the importance of international collaboration in establishing a North American supply for REEs and the strategic importance of such a supply chain to varied national interests
• Ucore intends to begin construction later this year on a commercial-scale REE production facility in Louisiana that expects to develop a production capacity of 2,000 metric tons of total rare earth oxides (“TREOs”) next year, increasing to 5,000 metric tons in 2025

Critical tech metal supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) recently welcomed U.S. Embassy staff members on a tour of the company’s test demonstration facility in Ontario, showcasing the strategic international importance of Ucore’s rare earth element (“REE”) technology.

Ucore has developed a proprietary solution for processing REEs, which are metals regarded as critical to modern magnets used worldwide in a wide range of products that include Apple’s iPhone, Tesla’s Model 3 electric vehicle, Lockheed Martin’s F-35 fighter jet, and similarly computer-dependent technology.

Ucore is introducing its RapidSX(TM) processing solution as a faster, more environmentally conscious REE ore extraction alternative to the standard SX process used throughout the industry. And because The People’s Republic of China effectively controls the supply chain for REEs and other tech metals, Ucore’s North America base for RapidSX(TM) has the potential to help wrest REE infrastructure for domestic product security and reliability.

“We were thrilled to welcome the U.S. Embassy staff to our Kingston Demo Plant. This visit underscores the significance of our work in the rare earth minerals sector and highlights our dedication to pioneering eco-friendly resource solutions,” Ucore VP and COO Mike Schrider, P.E., stated in the company’s Aug. 29 news release (https://ibn.fm/zoVGx).

“We believe that collaborations on an international level will play a pivotal role in shaping the future of sustainable technologies,” Schrider added, “and strengthen our position of applying pioneering technological breakthroughs to bolster our forthcoming commercial rare earth separation facility in Alexandria, Louisiana.”

The Louisiana plant is expected to begin construction later this year, leading to commercialization of Ucore’s RapidSX(TM) technology. The company anticipates building up to a production capacity of 2,000 metric tons of total rare earth oxides (“TREOs”) next year and then increasing it to 5,000 metric tons in 2025.

“If you’re making a chemical concentrate, or any type of concentrate, from a rare earth mine, you have no option today other than to send it to China for processing and it will get used in Chinese processing at that time. It will get used in F-35 fighters. … That’s not right,” Ucore CEO Pat Ryan said in an interview with InvestorIntel last year (https://ibn.fm/cpEP9).

The embassy representatives were given an exclusive tour of the Ontario demo plant, whose exclusive purpose is to showcase how the RapidSX(TM) process and the conventional SX process compare in their output ahead of the construction of the commercial-scale plant in Louisiana.

Ucore’s plans and the embassy staff visit underscore the potential for establishing international collaboration in securing freedom of product movement in the REE supply chain. The U.S. Department of Defense’s Industrial Base Analysis and Sustainment (“IBAS”) Program recently announced it has awarded a $4 million grant to Ucore to help it demonstrate the importance of RapidSX(TM) to national interests (https://ibn.fm/qxmCh).

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• D-Wave introduced algorithmic updates to its Constrained Quadratic Model (“CQM”) solver, delivering increased performance for existing binary problem classes, including offer allocation, portfolio optimization, and satisfiability
• D-Wave tested 2,045 binary quadratic problems, with the new CQM solver winning 80% of the problems against prior versions
• D-Wave’s hybrid solvers expand the size and complexity of potential problems customers can solve using classical and quantum computation to find better answers to complex business problems

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced an update to its Constrained Quadratic Model (“CQM”) hybrid solver in its Leap(TM) quantum cloud service. The company introduced algorithmic updates to its CQM solver, delivering increased performance for existing binary problem classes, including offer allocation, portfolio optimization, and satisfiability (https://ibn.fm/1AGIY).

D-Wave’s Advantage(TM) quantum computer is the first and only quantum computer designed for business applications. The platform features a processing architecture with over 5,000 qubits and 15-way connectivity. The Advantage system features 2.5x more connections and more than double the number of qubits than the company’s first-generation quantum computer model.

Optimization problems are everywhere in today’s enterprises, and the current quantum-hybrid technology available may help developers tackle quadratic problems to find better solutions. To provide a benchmark of the performance enhancements made to its updated hybrid solver, D-Wave tested 2,045 binary quadratic problems, with the new CQM solver winning 80% of the problems against prior versions. The full technical report can be found at https://ibn.fm/hzcCJ. 

D-Wave offers several hybrid solvers, which combine the power of classical and quantum computation to solve customers’ complex business problems. D-Wave’s hybrid solvers are available in the Leap quantum cloud service. Some of these solvers make use of NVIDIA GPUs accessed through cloud infrastructure.

“Our mission at D-Wave is to unlock the power of practical quantum computing for our customers. These most recent updates to our CQM hybrid solver reflect our commitment to building solutions that bring real enterprise applicability and impact today,” said Trevor Lanting, vice president of software, algorithms, and cloud services for D-Wave. “We’re excited by the performance enhancements that we are seeing, and our rapid pace of innovation allows us to expand quantum-hybrid workflows to help solve increasingly complex problems.”

As the only quantum computing company capable of solving real-world business problems today, D-Wave has helped customers build hundreds of practical quantum applications spanning logistics, artificial intelligence, materials sciences, drug discovery, employee scheduling, national defense, and financial modeling (https://ibn.fm/UQ7Jl). Some of the customers that D-Wave works with include Forbes Global 2000 companies and blue-chip industry leaders like Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin.

D-Wave owns one of the industry’s largest quantum computer intellectual property portfolios, including more than 210 issued US patents, and has published more than 100 peer-reviewed papers in leading scientific journals.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of today’s quantum hybrid technologies to help developers tackle quadratic problems to find better solutions. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of the company’s solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of its business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022, and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

• Electronic Servitor Publication Network, a technology-oriented digital engagement and activation company, is pioneering an evolution of digital marketing through its Digital Engagement Engine(TM), for the next generation of technology-enabled businesses
• Experts hold that sales leaders will need to rethink better ways to meet buyers’ inflated digital expectations
• As technology advances, companies are poised to move beyond simple automation and assisted selling to true augmented selling, where technology is positioned to play an active role in the design and execution of the sales process
• XESP is deploying its tech stack to create meaningful connections and drive the evolution of digital marketing

Technology is central to unlocking seller productivity and facilitating high-quality deals. However, according to Gartner, this is only possible when companies embrace technology and its applications as a teammate for sellers rather than merely a tool or a replacement. When looked at from this perspective, and amid a tech revolution that is giving technology more responsibility, new technological systems have the potential to transform the role of the seller, according to Robert Blaisdell, a Senior Director Analyst in Gartner’s Sales Practice (https://ibn.fm/oOIPA).

“A new approach that marries technology advances with the distinctive abilities that human sellers bring to a deal is required to adapt to customers’ changing needs and drive real commercial outcomes,” explains Blaisdell. “Sales leaders will need to rethink how to meet buyers’ inflated digital expectations. Those who don’t risk distancing themselves from buyers and leaving money on the table.”

As technology advances, it is increasingly playing a greater role and becoming fully embedded into operations. As a result, a recent article in Destination CRM notes (https://ibn.fm/8jqXe), companies “can finally move beyond simple automation and assisted selling to true augmented selling, where technology plays an active role in design and execution of the sales process.” Accordingly, sellers can rely on technology as their teammates, enabling them to assign or delegate roles associated with basic customer interactions or lead generations.

Some of the technologies that experts recognize as the top sales priorities in 2023 include content management, generative AI-powered email, digital sales rooms (“DSRs”), customer data platforms, digital engagement platforms, visual collaboration tools, virtual reality (“VR”), no-code workflows, workstream collaboration, conversational intelligence, visual configuration, narrative automation, buyer intent data collection tools, forecasting technology, and ChatGPT.

Amid recognition of the role that these technologies are poised to play in the future of sales and business, technology providers like Electronic Servitor Publication Network (OTCQB: XESP) are emerging to serve the next generation of technology-enabled businesses. XESP, a technology-oriented digital engagement and activation company, is pioneering the next step in the evolution of digital marketing with its Digital Engagement Engine(TM).

“Our Digital Engagement Engine isn’t just another marketing tool. It’s a way to develop real connections with your target market. And it’s the future of marketing,” explains the company. As the future of marketing, the Digital Engagement Engine is built on a robust stack of cutting-edge data analysis tools, smart technologies, and microservices, which, combined, enable it to identify the narrowest of niches within a company’s target market, create content that meets customers’ exact needs, and deliver content at the right moment when customers need it.

The company’s tools (a combination of its unique tech stack and proven processes) provision content, ensuring the message is well understood and is delivered in such a way that maximizes its potential for influence across both targeted audiences and new communities a company would like to engage. The tools also sort metadata, prior to launch, that will create the broadest of interest impacting both direct and indirectly related communities (https://ibn.fm/1sf91).

Upon launch, the tools analyze the initial launch data, autotune themselves, and begin redirecting to increase the reach of the content across online communities through omnichannel publications. Finally, the tech stack and tools loop back to the previously learned data – as well as any new data – enabling them to keep optimizing. In this regard, the tech stack continuously improves, driving better results for clients on a regular basis.

According to Electronic Servitor Publication Network’s case study, the company has already seen incredible results across multiple industries. Businesses within non-trending verticals, for example, are experiencing results that are nine times the industry average, while those within trending verticals are posting results that are seven times the industry standard (https://ibn.fm/kNeML).

In addition to blending several technologies that experts see as the top sales priorities in 2023 – including content management, digital engagement platforms, and more – XESP’s Digital Engagement Engine™ and processes are creating meaningful connections, driving the evolution of digital marketing, and serving the next generation of technology-enabled businesses.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• After a banner year in 2022, Prospera Energy remains poised for rapid growth in 2023; Prospera Energy Inc. recently announced the start of a 10-well horizontal drilling campaign that is intended to capture significant remaining heavy oil reserves
• The company aims to demonstrate that the coexistence of growth and sustainability is possible; seeks to capitalize on the high-margin potential of its core Canadian properties while steering the oil industry towards greener oil operations and a more sustainable future
• The company’s high aspirations come amid a burgeoning oil and gas market in Canada, for which 2023 is expected to be one of the pivotal moments

Following its transformational efforts in 2022, Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focused on Western Canada, appears poised for record growth in 2023. Building on the success from 2022, when the company realized a Net Income of $3.1 million and experienced rapid growth when its revenue grew by a staggering 860% in Q2 2022. Prospera Energy expects significant reductions in production costs through 2024 and sizable increases in daily production. The company is currently exploring strategic acquisition targets to diversify Prospera heavy/light/gas product mix and path to 5,000 BPD over the next 24 months while expanding its reserve base to a billion barrels (https://ibn.fm/mYttq).

The company recently announced the spudding of the first horizontal well of the ten well modular multi-pad infill drill program, which is intended to accelerate production and recovery to capture the significant remaining heavy oil reserves (400 MMBBL). Stemming from a comprehensive geological, seismic, and reservoir management delineation, this ten well program can approximately add new 750 BPD at a low decline to Prospera’s current 900+ BOEPD (https://ibn.fm/WdpH5).

The company’s high aspirations come amid a growing oil and gas market. “The year 2023 may be one of the most pivotal moments in time for Canada’s oil and natural gas industry,” said Lisa Baiton, the president and CEO of The Canadian Association of Petroleum Producers (“CAPP”). CAPP expects oil and natural gas investment in upstream production to beat pre-COVID levels, hitting $29.4 billion in 2023. The total investment forecast is 11% more in additional spending than the previous year, mainly directed towards environmental protection and emission reduction technologies (https://ibn.fm/C5oe0).

Prospera Energy appears firmly committed to growth, but not at the cost of the environment. In an era where environmental sustainability takes center stage, companies across the economy rush to rethink their operations in a bid to curb their impact on the planet – and oil and gas remains no exception. Traditionally entrenched in carbon-intensive practices, the industry has been notorious for contributing to pollution.

However, in a world that seeks to strike a balance between energy needs and environmental sustainability, those times are changing. Although taunted for worsening global warming, the industry is still considered well-positioned to become one of the strongest allies in the fight against the climate crisis, as the sector can help slash greenhouse gas emissions for future generations by leveraging its ample scientific and engineering expertise.

In this race towards a more sustainable future the company is committed to being part of the trailblazing pack that aims to set new benchmarks for more responsible oil production. By employing advanced technologies and innovative practices, the company strives to slash or even potentially eliminate emissions associated with its operations, showcasing its dedication to sustainable energy production (https://ibn.fm/wF5pN).

Leveraging a seasoned leadership team with more than 100 years of combined experience across multiple areas of business operations and growth strategy, Prospera Energy appears poised to show how growth and responsibility can coexist. Aspiring to change the face of the oil and gas industry, criticized for its contribution to global warming, the company seeks to eliminate emissions, minimize environmental impact, and run environmentally sustainable operations while capitalizing on the high-margin potential of its core Canadian properties in Saskatchewan and Alberta.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF